The transaction is sourced from two SEC EDGAR filings: one of unknown form type published on March 6, 2026, and a Form 424B4 prospectus also published on March 6, 2026. Based on the facts provided, the deal's status is pending regulatory approval.
The underwriting syndicate for this secondary offering is structured around a group of global coordinators and joint bookrunning managers, each identified as holding lead status. Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan are all named as global coordinators and joint bookrunning managers for the issuer, Medline. The source material lists these four firms together repeatedly under the heading "Global Coordinators and Joint Bookrunning Managers," confirming a shared lead role across the syndicate on this offering.
No legal advisor is identified for the issuer or for the underwriting syndicate in the facts provided for this transaction.
Beyond confirming that this is a secondary offering of common stock with a disclosed value of 3,075,000,000 dollars, no further detail on the number of shares offered, the offering price per share, or the identity of the selling stockholders is included in the facts available.
A number of elements of this deal remain undisclosed. No legal advisor to the issuer or underwriters is identified, and no detail is provided on the per-share offering price, the number of shares sold, or the identity of the selling stockholders in this secondary offering. The facts also do not specify an expected closing or settlement date.